AM has different oncogenic drivers from the cutaneous melanoma, including fewer BRAF mutations (10–23%), inconstant KIT mutation rates (3–29%), CCND1 and CDK4 amplification, and deletion or mutations in different genes, such as CDK2NA, PTEN, NF1, and hTERT (2, 5). The gene discussed is PTEN; the disease is cutaneous melanoma.